IOVANCE is working to cure cancer, developing transformative immuno-oncology TIL therapies harnessing a patient's immune system.

DISCOVER

TIL (Tumor Infiltrating Lymphocytes) technology is an ideal cancer therapy targeting heterogeneous solid tumors.

EXPLORE

TIL's unique qualities include single treatment, no maintenance or follow-up therapy, and broad-spectrum antigen specificity ideally suited for many solid tumor cancers.

LEARN
ADVANCING IMMUNO-ONCOLOGY

IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)

CLINICAL TRIALS

IOVANCE is conducting five Phase 2 clinical trials to assess the efficacy and safety of autologous Tumor Infiltrating Lymphocytes for treatment of patients with Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-Small Cell Lung Cancer (NSCLC) and Cervical Cancer.

C-144-01 is a multicenter clinical trial for patients with Metastatic Melanoma at various sites in the US and Europe.

C-145-03 is a multicenter clinical trial now recruiting patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at various sites in the US.

IOV-LUN-201 is a multicenter clinical trial now recruiting patients with Non-Small Cell Lung Cancer (NSCLC) at various sites in the US.

C-145-04 is a multicenter clinical trial now recruiting patients with Cervical Carcinoma at various sites in the US and Europe.

IOV-COM-202 is a multicenter clinical trial now recruiting patients with Solid Tumors at various sites in the US.

Learn
Latest News

News

March 7, 2019 IOVANCE BIOTHERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES IN MARCH

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that company management will participate and present at the following investors conferences in March: Cowen and Company 39th Annual Health Care Conference in Boston, March 11-13, 2019.

February 27, 2019 Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported its fourth quarter and year-end 2018 financial results and provided a corporate update.

February 26, 2019 Iovance Biotherapeutics was Granted Fast Track Designation for LN-145 for Cervical Cancer

Iovance Biotherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LN-145 for the treatment of patients with recurrent, metastatic or persistent cervical cancer who have progressed while on or after chemotherapy. LN-145 is the Company's adoptive cell therapy produced using its proprietary TIL manufacturing technology.

All News

Sign up for email alerts

Be the first to receive breaking news

Join